An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...
The results of a randomized controlled trial (RCT) indicate that meningococcal B vaccine is not effective at preventing ...
A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people who already have one, a new study shows. Semaglutide (also known as Ozempic) ...
A randomized trial of hospitalized patients with moderate hyponatremia compared targeted sodium correction versus routine care on mortality and rehospitalization rates.
Racial disparities on incidence and survival in Kaposi sarcoma during the post-retroviral era: A Surveillance, Epidemiology and End Results program database (2000-2021) retrospective analysis. This is ...
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...
‘A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial’ by David Erritzoe et al. was published in Nature Medicine at 16:00 UK time on ...
Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results